Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

about

Current and future biomarkers in colorectal cancer.Colorectal cancer genomics and designing rational trials.Differences in gene mutations according to gender among patients with colorectal cancer.

P2860

Q43492228-7195B6E4-8589-40A4-A257-A6729074A68E Q55306266-34240938-65C9-4EA2-B35A-7D8BB518E00C Q55473473-DB0A13ED-911C-4187-A8D3-825F55196A74

P2860

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

Item

http://www.wikidata.org/entity/Q40226443

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical Features and Outcomes ...... cers Harboring NRAS Mutations.

@en

type

Item

label

Clinical Features and Outcomes ...... cers Harboring NRAS Mutations.

@en

prefLabel

Clinical Features and Outcomes ...... cers Harboring NRAS Mutations.

@en

P1476

Clinical Features and Outcomes ...... cers Harboring NRAS Mutations.

@en

P2093

Andrea Cercek

http://www.w3.org/2001/XMLSchema#string

Joanne F Chou

http://www.w3.org/2001/XMLSchema#string

Leonard Saltz

http://www.w3.org/2001/XMLSchema#string

Maria Ignez Braghiroli

http://www.w3.org/2001/XMLSchema#string

Marinela Capanu

http://www.w3.org/2001/XMLSchema#string

Nancy Kemeny

http://www.w3.org/2001/XMLSchema#string

Rona Yaeger

http://www.w3.org/2001/XMLSchema#string

P2860

Colorectal Cancer in African Americans: An Update

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

NRAS mutations are rare in colorectal cancer.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

P304

4753-4760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-0400

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jaclyn F Hechtman

P577

2017-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28446505

http://www.w3.org/2001/XMLSchema#string

P932

5788017

http://www.w3.org/2001/XMLSchema#string

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

about

P2860

P2860

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932